Benedetto Farsaci

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes, Armando Santoro, Margaret A. Shipp et al. · The Lancet Oncology · 2016 · 924 citations · Full text

Medicine, Hematology, Oncology +16

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

Philippe Armand, Andreas Engert, Anas Younes et al. · Journal of Clinical Oncology · 2018 · 754 citations · Full text

Medicine, Hematology, Oncology +17

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader et al. · Journal of Clinical Oncology · 2018 · 367 citations · Full text

Life Sciences, Immunology, Oncology +17

Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

James W. Hodge, Charlie Garnett‐Benson, Benedetto Farsaci et al. · International Journal of Cancer · 2013 · 284 citations · Full text

Medicine, Oncology, Pharmacology +17

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

Mario Roselli, Vittore Cereda, Maria Giovanna di Bari et al. · OncoImmunology · 2013 · 186 citations · Full text

Medicine, Immunology, Oncology +17